Weight & Metabolic
What Happens to Blood Sugar After Stopping a GLP-1?
The short answer
In the tirzepatide withdrawal trial that tracked this directly, HbA1c drifted upward in step with how much weight came back — from a 0.14 percentage-point rise in people who regained the least, to a 0.35 point rise in people who regained 75% or more of their treatment-phase weight loss. Fasting insulin resistance rebounded even faster. A review pooling over 289,000 patients across observational cohorts estimates glycemic, blood pressure, and lipid markers drift back toward baseline within about a year of stopping. But the two largest randomized withdrawal trials both excluded people who actually had type 2 diabetes — so the cleanest data on this question comes from a population that wasn't diabetic to begin with.
Quick answers
- What is it?
- What happens to blood sugar and other cardiometabolic markers after someone stops taking a GLP-1 medication like semaglutide or tirzepatide.
- Why are people interested in it?
- Many people take these drugs for weight loss and want to know whether stopping will cause their blood sugar to rebound.
- What has actually been studied?
- A post hoc analysis of a randomized withdrawal trial (SURMOUNT-4) grouping people by how much weight they regained after switching from tirzepatide to placebo, plus a review pooling randomized withdrawal trials and observational cohorts of more than 289,000 patients.
- How strong is the evidence?
- Randomized controlled trial evidence, but the two largest withdrawal trials excluded people who actually had type 2 diabetes, so it doesn't directly describe a diagnosed diabetic patient's glycemic rebound.
- What don't we know yet?
- How blood sugar behaves in people who had diagnosed type 2 diabetes at baseline and stopped, whether tapering the dose changes the trajectory, and what happens beyond 12 to 18 months off the drug.
- Where can I read the original research?
- Sources at the bottom of this page: Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial and Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists.
The short answer: The most direct evidence comes from a post hoc analysis of the SURMOUNT-4 tirzepatide trial, which tracked cardiometabolic markers by how much weight participants regained after being switched to placebo. HbA1c rose in step with regain — from +0.14 percentage points in those who regained the least, up to +0.35 points in those who regained 75% or more of what they'd lost. Fasting insulin, a marker of insulin resistance, moved even more sharply. A separate review pooling data from more than 289,000 patients estimates that glycemic, blood pressure, and lipid markers generally drift back toward pre-treatment baseline within about a year of stopping. The catch: neither major randomized withdrawal trial enrolled people who actually had type 2 diabetes at the start.
What the research shows
The clearest data: SURMOUNT-4's regain categories
SURMOUNT-4 was built to test what continued tirzepatide treatment does versus stopping it. After a 36-week open-label lead-in in which participants lost an average of 20.9% of body weight, 670 people were randomized to continue tirzepatide or switch to placebo for another 52 weeks. A 2026 post hoc analysis took the placebo-switched group and split them by how much of their treatment-phase weight loss they regained by week 88: under 25%, 25–50%, 50–75%, and 75% or more.
The pattern was consistent across markers. HbA1c rose by 0.14 percentage points (95% CI 0.06 to 0.22) in the lowest-regain group, climbing to 0.15, then 0.27, then 0.35 points (CI 0.29 to 0.41) in the highest-regain group — a statistically significant trend (P<0.001). Waist circumference told the same story: unchanged in the low-regain group, up 14.7 cm in the high-regain group. Systolic blood pressure rose from 6.8 mmHg to 10.4 mmHg across the same categories. Fasting insulin showed the largest relative swing of any marker — up 46.2% in the 50–75% regain group — though the confidence intervals were wide. Participants who kept off at least 75% of their lost weight showed no significant change in waist circumference, non-HDL cholesterol, or fasting insulin compared with where they stood at week 36.
The broader synthesis
A 2026 review pulled together evidence from randomized withdrawal trials — including the STEP 1 extension, STEP 4, and SURMOUNT-4 — plus real-world observational cohorts totaling more than 289,000 patients. It described discontinuation as producing substantial weight regain (60–90% within a year in various cohorts) with a parallel reversal of cardiometabolic gains. Its modeling estimate: glycemic, blood pressure, and lipid parameters return toward baseline within roughly 12 months, with HbA1c normalizing over a slightly longer window of 12 to 18 months. The same review flagged that early discontinuation — stopping within the first year — was associated with increased risk of coronary artery disease and heart failure compared with staying on therapy, and attributed the regain itself to biological adaptations that follow weight loss, including reactivated hunger signaling and adaptive slowing of metabolism.
The semaglutide data, with a caveat
The STEP 1 trial extension is the other major withdrawal dataset, but it answers a narrower question than it's often cited for. STEP 1 enrolled 1,961 adults with obesity without diabetes. In the 327 participants followed for a year after both the drug and lifestyle program were stopped, cardiometabolic improvements that had appeared during 68 weeks of treatment moved back toward baseline over that year, in parallel with the two-thirds of lost weight that came back. But because the trial population didn't have diabetes at baseline, its glucose-related findings describe glycemic markers in metabolically healthier people, not the trajectory of someone managing diagnosed type 2 diabetes who stops treatment.
Why the population matters here
This is the detail that's easy to miss: SURMOUNT-4 also excluded diabetes from its main trial population. So the two largest, most rigorously controlled randomized withdrawal trials in this space — the ones actually built to isolate the effect of stopping the drug — were both conducted in people who didn't have type 2 diabetes to begin with. Their HbA1c changes are real and measured, but they describe a population moving within a largely non-diabetic range, not a diabetic patient's glycemic control unraveling after their prescription lapses.
What we don't know yet
How blood sugar behaves in people who had diagnosed type 2 diabetes at baseline and then stopped. The two flagship randomized withdrawal trials excluded this population outright. Everything about diabetic glycemic rebound after discontinuation is currently inferred from other sources, not measured directly in a controlled trial built for the question.
Whether tapering the dose changes the trajectory. Every trial compared full-dose continuation against a switch to placebo. No trial has tested a gradual step-down against abrupt stopping.
What happens after 12 to 18 months off the drug. The longest follow-up in the randomized data is about a year. Whether markers plateau, continue drifting, or partially stabilize past that point is not established.
Whether restarting recovers control at the same rate as the first course. People who stop and later resume GLP-1 therapy are common in practice, but no published trial has tracked whether a second course brings blood sugar back down as effectively, or on the same timeline, as it did originally.
How much individual variation there is, and what predicts it. The SURMOUNT-4 analysis grouped people by how much weight they regained, but what determines whether someone lands in the low-regain or high-regain group in the first place is not resolved.
Sources
- Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Internal Medicine, 2026;186(2):157–167. DOI
- Shah E, AlShiab R, Abdo A, et al. Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists. Diabetes, Obesity & Metabolism, 2026;28(6):4546–4558. DOI
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity & Metabolism, 2022;24(8):1553–1564. DOI
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024;331(1):38–48. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Weight & Metabolism | Evidence Index: semaglutide · tirzepatide
Sources
- Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial
- JAMA Internal Medicine, 2026 · n=308 · DOI
- Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists
- Diabetes, Obesity & Metabolism, 2026 · DOI
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
- Diabetes, Obesity & Metabolism, 2022 · n=327 · DOI
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
- JAMA, 2024 · n=670 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.